Protagenic Therapeutics, Inc. (PTIXW)

US — Healthcare Sector
Peers: IINNW  TCBPW  NRACW  MACAW  EDTXW 

Automate Your Wheel Strategy on PTIXW

With Tiblio's Option Bot, you can configure your own wheel strategy including PTIXW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PTIXW
  • Rev/Share 0.0
  • Book/Share -0.1688
  • PB -20.3756
  • Debt/Equity 0.0
  • CurrentRatio 0.8618
  • ROIC 61.2542

 

  • MktCap 2987344.0
  • FreeCF/Share -6.9294
  • PFCF -0.824
  • PE -0.3434
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -8.6052

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Protagenic Therapeutics, Inc. (PTIXW)

  • IPO Date 2021-04-27
  • Website http://www.protagenic.com
  • Industry Biotechnology
  • CEO Dr. Garo H. Armen Ph.D.
  • Employees 1
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.